The main mechanism of action and indications of momelotinib

Momelotinib (Momelotinib) is an oral multi-target tyrosine kinase inhibitor that mainly targets the Janus kinase (JAK) familyJAK1 and JAK2, also have the activity of inhibiting ACVR1, a component of the bone morphogenetic protein signaling pathway. This mechanism of action gives molotinib unique advantages in regulating inflammatory responses, inhibiting abnormal hematopoiesis, and improving anemia.

In myeloproliferative diseases where theJAK-STAT signaling pathway is abnormally active, such as primary myelofibrosis (PMF) and secondary myelofibrosis (including true myelofibrosis) Myelofibrosis evolved from polycythemia and essential thrombocythemia), molotinib inhibits JAK1/2 activity and blocks abnormal signaling of related cytokines, thereby reducing splenomegaly, improving systemic symptoms, and inhibiting disease progression.

Compared with otherJAK inhibitors, molotinib has obvious advantages in improving myelofibrosis-related anemia. This effect is related to its inhibition of ACVR1, allowing it to block the upregulation of a liver-synthesized hormone called hepcidin, an important regulator of iron homeostasis. By reducing hepcidin levels, molotinib helps increase iron utilization and improve red blood cell production, thereby alleviating patients' anemia symptoms and reducing transfusion dependence.

Molotinib is currently mainly suitable for the treatment of patients with intermediate- and high-risk myelofibrosis, especially those with anemia. In multiple clinical trials, molotinib has performed well in improving spleen volume, relieving symptoms, and improving quality of life. At the same time, its positive effect on anemia gives it certain therapeutic advantages over existing JAK inhibitors. In the future, molotinib is expected to become one of the first-line treatment options for patients with myelofibrosis.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib